CSNK2A1 Recombinant Monoclonal Antibody

說明書

中文名稱：

CSNK2A1重組抗體
貨號：

CSB-RA964915A0HU
規格：

￥1320
圖片：
Western Blot
Positive WB detected in: NIH/3T3 whole cell lysate, 293 whole cell lysate, Jurkat whole cell lysate, Hela whole cell lysate, A549 whole cell lysate, U-87 whole cell lysate
All lanes: CKII alpha antibody at 1:1000
Secondary
Goat polyclonal to rabbit IgG at 1/50000 dilution
Predicted band size: 46, 30 kDa
Observed band size: 45 kDa
其他：

產品詳情
產品評價
相關產品
靶點詳情

產品詳情

產品描述：

CSNK2A1 Recombinant Monoclonal Antibody（CSB-RA964915A0HU）是一款針對酪蛋白激酶2α1（CSNK2A1）的高特異性抗體，適用于酶聯免疫吸附實驗（ELISA）和蛋白質免疫印跡（WB）檢測。該抗體靶向的CSNK2A1是絲氨酸/蘇氨酸蛋白激酶CK2的核心催化亞基，廣泛參與細胞增殖、凋亡調控及DNA損傷修復等關鍵生物學過程，是細胞信號轉導網絡的重要調控因子。經實驗驗證，該抗體在WB應用中表現出優異的靈敏度和特異性，推薦稀釋比例為1:500至1:5000，可在多種樣本類型中檢測目標蛋白的表達水平，并提供清晰的檢測信號。其在基礎研究中的應用涵蓋CSNK2A1相關信號通路的功能解析、腫瘤發生機制探索以及蛋白質相互作用研究等領域，為探究該激酶在細胞周期調控、代謝穩態及疾病模型中的作用提供可靠工具。本產品嚴格適用于科研場景，包括但不限于分子生物學實驗、疾病機制研究及藥物靶點篩選。
Uniprot No.：

P68400
基因名：

CSNK2A1
別名：

Casein kinase II subunit alpha (CK II alpha) (EC 2.7.11.1), CSNK2A1, CK2A1
反應種屬：

Human, Mouse
免疫原：

A synthesized peptide derived from human CKII alpha
免疫原種屬：

Homo sapiens (Human)
標記方式：

Non-conjugated
克隆類型：

Monoclonal
抗體亞型：

Rabbit IgG
純化方式：

Affinity-chromatography
克隆號：

2B6
濃度：

It differs from different batches. Please contact us to confirm it.
保存緩沖液：

Rabbit IgG in 10mM phosphate buffered saline , pH 7.4, 150mM sodium chloride, 0.05% BSA, 0.02% sodium azide and 50% glycerol.
產品提供形式：

Liquid
應用范圍：

ELISA, WB

推薦稀釋比：

Application	Recommended Dilution
WB	1:500-1:5000

Protocols：

ELISA Protocol
Western Blotting (WB) Protocol
儲存條件：

Upon receipt, store at -20°C or -80°C. Avoid repeated freeze.
貨期：

Basically, we can dispatch the products out in 1-3 working days after receiving your orders. Delivery time maybe differs from different purchasing way or location, please kindly consult your local distributors for specific delivery time.
用途：

For Research Use Only. Not for use in diagnostic or therapeutic procedures.

產品評價

靶點詳情

功能：

Catalytic subunit of a constitutively active serine/threonine-protein kinase complex that phosphorylates a large number of substrates containing acidic residues C-terminal to the phosphorylated serine or threonine. Regulates numerous cellular processes, such as cell cycle progression, apoptosis and transcription, as well as viral infection. May act as a regulatory node which integrates and coordinates numerous signals leading to an appropriate cellular response. During mitosis, functions as a component of the p53/TP53-dependent spindle assembly checkpoint (SAC) that maintains cyclin-B-CDK1 activity and G2 arrest in response to spindle damage. Also required for p53/TP53-mediated apoptosis, phosphorylating 'Ser-392' of p53/TP53 following UV irradiation. Can also negatively regulate apoptosis. Phosphorylates the caspases CASP9 and CASP2 and the apoptotic regulator NOL3. Phosphorylation protects CASP9 from cleavage and activation by CASP8, and inhibits the dimerization of CASP2 and activation of CASP8. Regulates transcription by direct phosphorylation of RNA polymerases I, II, III and IV. Also phosphorylates and regulates numerous transcription factors including NF-kappa-B, STAT1, CREB1, IRF1, IRF2, ATF1, ATF4, SRF, MAX, JUN, FOS, MYC and MYB. Phosphorylates Hsp90 and its co-chaperones FKBP4 and CDC37, which is essential for chaperone function. Mediates sequential phosphorylation of FNIP1, promoting its gradual interaction with Hsp90, leading to activate both kinase and non-kinase client proteins of Hsp90. Regulates Wnt signaling by phosphorylating CTNNB1 and the transcription factor LEF1. Acts as an ectokinase that phosphorylates several extracellular proteins. During viral infection, phosphorylates various proteins involved in the viral life cycles of EBV, HSV, HBV, HCV, HIV, CMV and HPV. Phosphorylates PML at 'Ser-565' and primes it for ubiquitin-mediated degradation. Plays an important role in the circadian clock function by phosphorylating ARNTL/BMAL1 at 'Ser-90' which is pivotal for its interaction with CLOCK and which controls CLOCK nuclear entry. Phosphorylates CCAR2 at 'Thr-454' in gastric carcinoma tissue.
基因功能參考文獻：
1. Casein kinase II, glycogen synthase kinase-3, and Ikaros mediated regulation of leukemia has been summarized. (Review) PMID: 28623166
2. Our results showcase the potentially valuable functional impact of microRNAs in regulating GG related epilepsy. As CK-2alpha inhibition enhances miR-217 expression, disrupting the miR-217-CK-2alpha interplay through CK-2alpha inhibitors might represent a novel therapeutic strategies aimed at LEAT. PMID: 28840260
3. The results suggest that CK2alpha promotes migration and invasion of clear cell renal cell carcinoma and therefore could serve as a novel prognostic biomarker and molecular therapeutic target in this type of cancer. PMID: 27906674
4. The newly designed casein kinase 2 (CK2) Inhibitors were screened on one lung cancer cell line A549, showing low micromolar anti-proliferative activity. PMID: 27491649
5. CK2 governs the molecular decision between encephalitogenic TH17 cells and protective Treg cells development. PMID: 27555590
6. Data suggest that casein kinase 2 (CK2) inhibition is a promising approach to blocking beta-catenin in MPNST cells, although combinatorial therapies may be required for maximal efficacy. PMID: 27448963
7. Results provide evidence that CK2A is critical fro RSV virus replication in human cells. PMID: 27464690
8. Vascular smooth muscle protein kinase CK2 inhibition suppresses neointima formation via a proline-rich homeodomain-dependent mechanism. PMID: 28927755
9. we have identified kinases, particularly CK2, associated with the autocrine malignant cell network that may play a central role in sustaining the cytokine network and/or mediating its effects in ovarian cancer. PMID: 26871292
10. CK2 and AKT display a high degree of cross-regulation of their respective functions, both directly, through physical interaction and phosphorylation, and indirectly, through an intense cross-talk of key downstream effectors, ultimately leading to sustained AKT activation. (Review) PMID: 28373060
11. Phosphorylation of Ikaros by CK2 impairs Ikaros DNA-binding ability, as well as Ikaros ability to regulate gene expression and function as a tumor suppressor in leukemia. (Review) PMID: 27666503
12. data implicate CK2 as a regulator of the Th17/Treg axis and Th17 cell maturation and suggest that CK2 could be targeted for the treatment of Th17 cell-driven autoimmune disorders. PMID: 28468969
13. This study demonstrates that CSNK2A1 and SIRT6 are indicators of poor prognosis for breast carcinomas and that CSNK2A1-mediated phosphorylation of SIRT6 might be involved in the progression of breast carcinoma. PMID: 27746184
14. Our results disclose a novel interplay between ubiquitin- and phosphorylation-dependent signalling, and represent the first report of a regulatory mechanism for UIM-dependent function. They also suggest that CK2 inhibitors could release the full neuroprotective potential of HSJ1, and deserve future interest as therapeutic strategies for neurodegenerative disease. PMID: 28031292
15. CK2 inhibition in monocyte-derived dendritic cells led to an enhanced Th2 polarization in the absence of contact sensitizer stimulation. PMID: 27707883
16. In the present work we have shown a key role for protein kinase CK2 in promoting LSC survival through the modulation of the STAT3, NF-kappaB and AKT/FOXO signaling pathways. We have also shown that CK2 inactivation makes LSCs more sensitive to the chemotherapeutic drug doxorubicin. PMID: 27479180
17. our findings establish an important regulatory role of CK2alpha on BMI1 phosphorylation and stability and implicate the CK2alpha/BMI1 axis in ovarian cancer. PMID: 28270146
18. The lack of intermediate species of CK2 alpha2beta2 in solution suggests that the holoenzyme is a strong/stable multimeric complex that does not spontaneously dissociate; a considerable amount of monomer, the active form of CK2, is present in low ionic strength solutions. Multimer assembly appears driven by electrostatic interactions between the CK2alpha P+1 loop and the CK2beta acidic loop. PMID: 28572157
19. These data support a role for casein kinase 2 in regulation of protein synthesis by downregulating stress granule formation through G3BP1. PMID: 27920254
20. The invasion and migration of A549 cells were significantly inhibited after the knockdown of CK2alpha expression. PMID: 28442011
21. Somatic mutations in CSNK2A1 have been implicated in various cancers; however, this is the first study to describe a human condition associated with germline mutations in any of the CK2 subunits PMID: 27048600
22. This study shows for the first time that LPS inhibits colonic biotin uptake via decreasing membrane expression of its transporter and that these effects likely involve a CK2-mediated pathway. PMID: 28052864
23. This study indicates that CKII can modulate the intracellular reactive oxygen species level via FoxO3a. PMID: 27470586
24. Twelve SNPs from four regions were significantly associated with aggressive disease, among which, three linked SNPs in CSNK1A1 at 5q32 (represented by rs752822) may differentiate GS 4+3 from GS 3+4 patients (OR = 1.44, 95% CI = 1.12-1.87, P = 4.76x10(-3)). PMID: 27515962
25. using a kinase-inactive mutant of CK2alpha, that RAF-MEK inhibitor resistance did not rely on CK2alpha kinase catalytic function, and both wild-type and kinase-inactive CK2alpha maintained ERK phosphorylation upon inhibition of BRAF or MEK. PMID: 27226552
26. Inhibition of CK2 increased the expression of metabolic regulators, PDK4 and AMPK along with the key cellular energy sensor CREB. PMID: 27001465
27. Report provides evidence that CSNK2A1 kinase hyperactivity occurs in vivo in all classes of glioblastomas independently of TP53 status as well as in glial tumors of lower grades and histology. PMID: 27098015
28. CK2-increased ECE-1c protein stability is related to augmented migration and invasion of colon cancer cells, shedding light on a novel mechanism by which CK2 may promote malignant progression of this disease. PMID: 26543229
29. This study report increased levels of CK2 in the hippocampus and temporal cortex of AD patients compared to non-demented controls. PMID: 26732432
30. CK2-mediated phosphorylation of ARC contributed to chemotherapy resistance by inhibiting DOX induced apoptosis; combining DOX with CK2 inhibitor could induce apoptosis of cancer cells synergistically by down-regulating the phosphorylation of ARC PMID: 26172393
31. Protein kinase CK2 expression predicts relapse survival in ERalpha dependent breast cancer, and modulates ERalpha expression in vitro. PMID: 26703694
32. Data suggest that complexes of HDAC3-H1.3 with NCOR1 and NCOR2/SMRT accumulate on chromatin in synchronized HeLa cells in late G2 phase and mitosis; deacetylation activity of HDAC3 is activated via phosphorylation of Ser-424 by CK2 only in mitosis. PMID: 26663086
33. ATG16L1 as a bona fide physiological CSNK2 and PPP1 substrate, which reveals a novel molecular link from CSNK2 to activation of the autophagy-specific ATG12-ATG5-ATG16L1 complex and autophagy induction PMID: 26083323
34. Data suggest that cryptochromes mediate periodic binding of Ck2b (casein kinase 2beta) to Bmal1 (aryl hydrocarbon receptor nuclear translocator-like protein) and thus inhibit Bmal1-Ser90 phosphorylation by Ck2a (casein kinase 2alpha). [SYNOPSIS] PMID: 26562283
35. The combination treatment of TRAIL and the CK2 inhibitor decreased p65 nuclear translocation... the treatment of a sub-dose of TRAIL, downregulation of CK2, using both genetic and pharmacological approaches . PMID: 26165401
36. our findings provide new insights on the potential relevance of the CK2-mediated phosphorylation of B23/NPM in cancer cells, revealing at the same time the potentialities of its pharmacological manipulation for cancer therapy PMID: 25805179
37. Inhibition of ecto-CK2 by K137-E4 is accompanied by a slower migration of cancer cells as judged by wound healing assays PMID: 26349539
38. CK2 is widely expressed in follicular, Burkitt and diffuse large B-cell lymphomas and may have role in malignant B-cell growth. PMID: 25788269
39. High casein kinase II expression is associated with B-cell acute lymphoblastic leukemia. PMID: 26219304
40. Data show that casein kinase 2 (CK2)-mediated phosphorylation of deubiquitylating enzyme OTUB1 at Ser16 causes nuclear accumulation of OTUB1. PMID: 25872870
41. Overall results, confirm that a balance of hydrophobic and electrostatic interactions contribute predominantly relative to possible intermolecular halogen/hydrogen bonding ,in binding of halogenated benzotriazoles to the ATP-binding site of hCK2alpha PMID: 25891901
42. These phosphopeptides include altogether 69 phosphoresidues, a large proportion of which (almost 50%) are generated by CK2, while the others do not conform to the CK2 consensus PMID: 25882195
43. Over-expressed CK2alpha positively regulate Hh/Gli1 signaling in human mesothelioma. PMID: 25422081
44. CDK11 and CK2 expression are individually essential for breast cancer cell survival, including TNBC. PMID: 25837326
45. There is a major role of the CK2alpha-interacting protein CKIP-1 in activation of PAK1 for neoplastic prostate cells transformation. PMID: 26160174
46. Casein kinase 2-mediated phosphorylation of Hsp90beta and stabilization of PXR is a key mechanism in the regulation of MDR1 expression. PMID: 25995454
47. Phosphorylation of KCNQ2 and KCNQ3 anchor domains by protein kinase CK2 augments binding to AnkG. PMID: 25998125
48. Results show that CK2alpha may have an important role in brain tumor-initiating cell maintenance through the regulation of beta-catenin in glioblastoma. PMID: 25241897
49. CK2-phosphorylation of eIF3j at Ser127 promotes the assembly of the eIF3 complex, a crucial step in the activation of the translation initiation machinery. PMID: 25887626
50. CK2 phosphorylates and inhibits TAp73 tumor suppressor function to promote expression of cancer stem cell genes and phenotype in head and neck cancer. PMID: 25379016
顯示更多

收起更多
相關疾病：

Okur-Chung neurodevelopmental syndrome (OCNDS)
亞細胞定位：

Nucleus.
蛋白家族：

Protein kinase superfamily, Ser/Thr protein kinase family, CK2 subfamily
組織特異性：

Expressed in gastric carcinoma tissue and the expression gradually increases with the progression of the carcinoma (at protein level).
數據庫鏈接：

HGNC: 2457

OMIM: 115440

KEGG: hsa:1457

STRING: 9606.ENSP00000217244

UniGene: Hs.644056

Most popular with customers

YWHAG Recombinant Monoclonal Antibody

Applications: ELISA, WB, IHC

Species Reactivity: Human
YWHAB Recombinant Monoclonal Antibody

Applications: ELISA, WB, IHC, IF, FC

Species Reactivity: Human, Mouse, Rat
Phospho-YAP1 (S127) Recombinant Monoclonal Antibody

Applications: ELISA, WB, IHC

Species Reactivity: Human
XPNPEP1 Recombinant Monoclonal Antibody

Applications: ELISA, IHC, FC

Species Reactivity: Human
XDH Recombinant Monoclonal Antibody

Applications: ELISA, WB, IHC

Species Reactivity: Human
WT1 Recombinant Monoclonal Antibody

Applications: ELISA, WB, IHC

Species Reactivity: Human
WFDC2 Recombinant Monoclonal Antibody

Applications: ELISA, WB, FC

Species Reactivity: Human
WDR5 Recombinant Monoclonal Antibody

Applications: ELISA, IHC, FC

Species Reactivity: Human